1. Cassava Sciences' stock is heavily shorted, with potential rewards tied to the upcoming Phase 3 trial results for simufilam. 2. The bull thesis hinges on simufilam outperforming current treatments or showing efficacy in specific subgroups. 3. Mixed trial results could still offer a path forward, but the stock's unpredictable nature and meme-stock characteristics add to the investment risk.